Instrument Inactif

Autres langues Biostage Inc Nasdaq

Actions

US41690A1060

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

13/05	Harvard Apparatus Regenerative Technology Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
28/03	Harvard Apparatus Regenerative Technology Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Harvard Apparatus Regenerative Technology : Q1 - 2024 HBIO Quarterly Earnings Presentation	07/05
Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding	15/04
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation	18/03
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation	07/03
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023	18/09/23
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation	08/08/23
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	19/07/23
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease	18/07/23
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors	15/06/23
Biostage to Host Investor Call	13/06/23
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease	31/05/23
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Biostage, Inc. announced that it has received $6.005802 million in funding	13/04/23
BIOSTAGE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	10/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Biostage Inc Nasdaq

Actions

US41690A1060

Autres langues

Filtres